Yayın:
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorŞimşek, Eda Tanrıkulu
dc.contributor.authorÜskent, Necdet
dc.contributor.authorEmel Mutlu
dc.contributor.authorMusa Barış Aykan
dc.contributor.authorMustafa Korkmaz
dc.contributor.authorSelim Yalçın
dc.contributor.authorTeoman Şakalar
dc.contributor.authorÖzde Melisa Celayir
dc.contributor.authorErkan Kayıkçıoğlu
dc.contributor.authorFerit Aslan
dc.contributor.authorEmre Hafızoğlu
dc.contributor.authorYunus Emre Altıntaş
dc.contributor.authorMerve Keskinkılıç
dc.contributor.authorElvin Chalabıyev
dc.contributor.authorAbdüssamet Çelebi
dc.contributor.authorBengü Dursun
dc.contributor.authorCaner Kapar
dc.contributor.authorMiraç Özen
dc.contributor.authorÖmer Acar
dc.contributor.authorÖzgecan Dülgar
dc.contributor.authorEngin Kut
dc.contributor.authorSedat Biter
dc.contributor.authorFatih Kuş
dc.contributor.authorElvina Almuradova
dc.contributor.authorAtike Pınar Erdoğan
dc.contributor.authorSeray Saray
dc.contributor.authorDeniz Can Güven
dc.contributor.authorEda Tanrıkulu Şimşek
dc.contributor.authorNecdet Üskent
dc.contributor.authorYasemi̇n Kemal
dc.contributor.authorBurcu Çakar
dc.contributor.authorÖzgür Açıkgöz
dc.contributor.authorSaadettin Kılıçkap
dc.contributor.authorSercan Aksoy
dc.contributor.orcid0000-0003-3060-377X
dc.contributor.orcid0000-0003-2184-634X
dc.contributor.orcid0000-0002-1008-2527
dc.contributor.orcid0000-0001-7538-9119
dc.contributor.orcid0000-0003-0926-6748
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0002-8562-7085
dc.contributor.orcid0000-0002-7401-5446
dc.contributor.orcid0000-0002-9153-6921
dc.contributor.orcid0000-0002-0634-7350
dc.contributor.orcid0000-0002-3342-3144
dc.contributor.orcid0000-0001-6470-6043
dc.contributor.orcid0000-0002-6922-1018
dc.contributor.orcid0000-0002-1433-8446
dc.contributor.orcid0000-0002-8879-8533
dc.contributor.orcid0000-0002-1934-0190
dc.contributor.orcid0000-0003-4408-1976
dc.contributor.orcid0000-0002-0678-4024
dc.contributor.orcid0000-0002-1053-0668
dc.contributor.orcid0000-0003-1650-154X
dc.contributor.orcid0000-0002-5551-7731
dc.contributor.orcid0000-0003-4859-7574
dc.contributor.orcid0000-0001-5916-6265
dc.contributor.orcid0000-0002-6924-9467
dc.contributor.orcid0000-0003-2739-7362
dc.contributor.orcid0000-0002-1175-9085
dc.contributor.orcid0000-0003-3790-791X
dc.contributor.orcid0000-0003-2715-4002
dc.contributor.orcid0000-0003-1637-7390
dc.contributor.orcid0000-0003-4984-1049
dc.date.accessioned2025-11-13T10:27:34Z
dc.date.issued2024-02-04
dc.identifier.doihttps://doi.org/10.1007/s10147-023-02460-5
dc.identifier.endpage265
dc.identifier.issn1341-9625
dc.identifier.issue3
dc.identifier.openalexW4391520083
dc.identifier.startpage258
dc.identifier.urihttps://hdl.handle.net/11421/4214
dc.identifier.urihttps://doi.org/10.1007/s10147-023-02460-5
dc.identifier.volume29
dc.language.isoen
dc.relation.ispartofInternational Journal of Clinical Oncology
dc.rightsrestrictedAccess
dc.subjectPalbociclib
dc.subjectMedicine
dc.subjectMetastatic breast cancer
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectBreast cancer
dc.subjectCancer
dc.subjectAdverse effect
dc.subjectSurgical oncology
dc.subjectGynecology
dc.subject.sdg3
dc.titleThe efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5019055570
local.authorid.openalexA5064757657

Dosyalar

Koleksiyonlar

Publications